These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2829376)

  • 1. Measurement of low molecular weight heparin ex vivo activities in clinical laboratories using various anti-Xa assays: interlaboratory variability and requirement for an agreed low molecular weight heparin standard.
    Sié P; Aillaud MF; de Prost D; Droullé C; Forestier F; Guedj P; Juhan-Vague I; Polack B; Potron G; Roncato M
    Thromb Haemost; 1987 Oct; 58(3):879-83. PubMed ID: 2829376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limitations of the chronometric assays to determine plasma antifactor Xa activity during low molecular weight heparin therapy.
    Boneu B; Faruel-Bille V; Pierrejean D; Gabaig AM
    Nouv Rev Fr Hematol (1978); 1991; 33(4):287-91. PubMed ID: 1664095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective.
    Favaloro EJ; Bonar R; Aboud M; Low J; Sioufi J; Wheeler M; Lloyd J; Street A; Marsden K;
    Lab Hematol; 2005; 11(3):157-62. PubMed ID: 16174600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
    Peyrou V; Béguin S; Boneu B; Hemker HC
    Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low molecular weight heparins: antithrombotic and haemorrhagic effects and standardization.
    Barrowcliffe TW; Thomas DP
    Acta Chir Scand Suppl; 1988; 543():57-64. PubMed ID: 2847459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A collaborative study of proposed European Pharmacopoeia reference preparations of low molecular mass heparin.
    Gray E; Heath AB; Mulloy B; Spieser JM; Barrowcliffe TW
    Thromb Haemost; 1995 Sep; 74(3):893-9. PubMed ID: 8571317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variability of plasma anti-Xa activities with different lots of enoxaparin.
    Gosselin RC; King JH; Janatpour KA; Dager WE; Larkin EC; Owings JT
    Ann Pharmacother; 2004 Apr; 38(4):563-8. PubMed ID: 14982983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heptest-STAT, a new assay for monitoring of low-molecular-weight heparins, is not influenced by pregnancy-related changes of blood plasma.
    Dempfle CE; Zharkowa U; Elmas E; Ahmad-Nejad P; Neumaier M; Borggrefe M
    Thromb Haemost; 2009 Nov; 102(5):1001-6. PubMed ID: 19888540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Biological monitoring of treatment with low molecular weight heparin].
    Aiach M; Sié P
    Ann Biol Clin (Paris); 1988; 46(9):715-8. PubMed ID: 2851948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability.
    Kitchen S; Iampietro R; Woolley AM; Preston FE
    Thromb Haemost; 1999 Oct; 82(4):1289-93. PubMed ID: 10544915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers.
    Eriksson BI; Söderberg K; Widlund L; Wandeli B; Tengborn L; Risberg B
    Thromb Haemost; 1995 Mar; 73(3):398-401. PubMed ID: 7667822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers.
    Azizi M; Veyssier-Belot C; Alhenc-Gelas M; Chatellier G; Billaud-Mesguish E; Fiessinger JN; Aiach M
    Br J Clin Pharmacol; 1995 Dec; 40(6):577-84. PubMed ID: 8703665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors.
    Calatzis A; Peetz D; Haas S; Spannagl M; Rudin K; Wilmer M
    Am J Clin Pathol; 2008 Sep; 130(3):446-54. PubMed ID: 18701419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative evaluation of unfractionated and low molecular weight heparins. Results of the French Etalonorme interlaboratory quality control].
    Houbouyan LL; Goguel AF
    Ann Biol Clin (Paris); 1993; 51(2):109-17. PubMed ID: 8214808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination.
    Grimaudo V; Omri A; Kruithof EK; Hauert J; Bachmann F
    Thromb Haemost; 1988 Jun; 59(3):388-91. PubMed ID: 2847348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An overview of clinical trials of low molecular weight heparin fractions.
    Levine MN; Hirsh J
    Acta Chir Scand Suppl; 1988; 543():73-9. PubMed ID: 2847461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An international standard for low molecular weight heparin.
    Barrowcliffe TW; Curtis AD; Johnson EA; Thomas DP
    Thromb Haemost; 1988 Aug; 60(1):1-7. PubMed ID: 2847351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Collaborative study for the establishment of replacement batches of heparin low- molecular-mass for assay biological reference preparations.
    Terao E; Daas A; Rautmann G; Buchheit KH
    Pharmeur Bio Sci Notes; 2010 Oct; 2010(2):30-6. PubMed ID: 21144487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.